Pre-surgery treatment study for unresectable gallbladder cancer
Part of Cancer clinical trials.
This Phase 2 trial tests a “before-surgery” (preoperative) treatment approach for gallbladder cancer that cannot be fully removed with an operation. It may help shrink or control the cancer and improve outcomes, especially if standard options have limits for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your caregiver) can sign informed consent and agree to the study procedures.
- You are age 18 to 75, and you have gallbladder cancer that cannot be fully removed (unresectable), or only non-curative/palliative surgery is possible.
- You have not had any whole-body (systemic) cancer treatment within the last 6 months.
- Your general health is good enough for treatment (ECOG 0–1).
- Your liver, kidney, blood counts, and thyroid tests fall within the study’s required ranges (and you must have at least one measurable tumor spot).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug camrelizumab with two chemotherapy drugs (gemcitabine and oxaliplatin, known as GEMOX) for people with gallbladder cancer that cannot be surgically removed. It aims to see if this treatment can help shrink the tumor and improve outcomes.
This Phase 2 trial studies whether adding a PD-1 antibody plus gemcitabine/oxaliplatin (GEMOX) after surgery can lower the chance of the cancer coming back in perihilar cholangiocarcinoma. It’s for people who have had surgery with no tumor left at the cut edges, but lymph nodes showed cancer under the microscope.
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
This Phase 2 trial tests a targeted treatment (GEMOX) given after gallbladder cancer surgery. It uses a blood test that looks for cancer-related DNA to monitor recurrence and guide care, aiming to improve outcomes for people with higher-risk disease.
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
This trial tests whether combining an immunotherapy drug (AK112) with chemotherapy can shrink advanced gallbladder cancer enough to make surgery possible. The goal is to give patients a chance at curative surgery who otherwise might not have one.
Hear when a new Unresectable Gallbladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.